Amphetamine (AMPH) induces behavioral sensitization and neurotoxicity primarily by enhancing the dopamine-mediated neurotransmission. However, the involvement of the N-methyl-D-aspartate (NMDA) receptor in AMPH-induced neuropathology is also known. Recent investigation has found that high concentration of dopamine could inhibit NMDA receptor-mediated responses by blocking the NMDA receptor channel. 3 H]TCP binding suggested that the high-potency inhibition was produced by decreasing agonist-induced activation of the NMDA receptor channel. On the other hand, the low-potency inhibition was produced by competing with [ 3 H]TCP binding in the NMDA receptor channel, like the action of noncompetitive antagonist of the NMDA receptor. However, AMPH analogs were less potent in inhibiting NMDA-and glycine-induced cultured cell death. Thus, this result indicates that AMPH could antagonize the NMDA receptor-mediated responses in vitro by two different mechanisms, probably, through directly interacting with two distinct sites on this receptor/channel complex.
H]TCP) binding in rat cortical membrane preparations and intracellular 45 Ca 2ϩ accumulation and cell death in the rat primary cortical cell cultures. AMPH concentration-dependently inhibited NMDA-and glycine-stimulated [ 3 H]TCP binding and intracellular 45 Ca 2ϩ accumulation with two distinct potencies; a minor inhibition with high potency and a major inhibition with low potency. [ 3 H]TCP binding suggested that the high-potency inhibition was produced by decreasing agonist-induced activation of the NMDA receptor channel. On the other hand, the low-potency inhibition was produced by competing with [ 3 H]TCP binding in the NMDA receptor channel, like the action of noncompetitive antagonist of the NMDA receptor. However, AMPH analogs were less potent in inhibiting NMDA-and glycine-induced cultured cell death. Thus, this result indicates that AMPH could antagonize the NMDA receptor-mediated responses in vitro by two different mechanisms, probably, through directly interacting with two distinct sites on this receptor/channel complex.
Amphetamine (AMPH), a commonly abused psychostimulant, induces behavioral sensitization or neurotoxcity primarily by enhancing the activities of dopaminergic systems (Robinson and Becker, 1986; Kalivas and Stewart, 1991; Segal and Kuczenski, 1992; Robinson and Berridge, 1993) . However, available evidences have indicated the involvement of the N-methyl-D-aspartate (NMDA) receptor, a subtype of glutamate receptors. Administration of NMDA receptor antagonists effectively prevented or attenuated a variety of AMPH-induced responses such as behavioral sensitization, neuronal degeneration, and gene expression, indicating that activation of the NMDA receptor is required for the development and expression of AMPH-induced neuropathological responses (Karler et al., 1989; Lowy, 1990; HemrickLuecke et al., 1992; Bristow et al., 1994; Wang et al., 1994; Konradi et al., 1996) . The recruitment of the NMDA receptormediated neurotransmission in AMPH-mediated response has been thought to be as a result of an increase in glutamate release Yamamoto, 1992, 1993) and an increase in the sensitivity to glutamate agonist (White et al., 1995) of the dopaminergic neurons after repeatedly being exposed to AMPH. Recent investigation had shown that dopamine at concentrations higher than 100 M was able to inhibit the NMDA receptor-mediated electrophysiological responses in a concentration-dependent manner by directly blocking the NMDA receptor channel (Castro et al., 1999) . Given that AMPH shares a structural similarity with dopamine ( Fig. 1) and that the dopamine transporter could potently uptake both compounds, we proposed that AMPH might be able to regulate directly the NMDA receptor-mediated activities. To test this possibility, we determined whether AMPH analogs could affect the NMDA receptor-mediated responses in vitro, including NMDA-and glycine-stimulated [ 3 H]TCP binding in membrane preparation of rat brain tissues and NMDA-and glycine-elicited intracellular 45 Ca 2ϩ accumulation and cell death in rat primary cortical cell cultures. The result of this study provided evidences that AMPH could directly inhibit the NMDA receptor-mediated responses by interacting with two distinct sites on this receptor/channel complex. acetate buffer containing 1 mM EDTA (pH 7.4, 4°C). The last five cycles of washing were performed in 5 mM tris-acetate buffer (pH 7.4, 4°C). Membranes were rapidly frozen in a methanol/dry ice bath, slowly thawed at room temperature before the third cycle of washing, and stored in Ϫ70°C for at least 24 h before the fourth cycle of washing.
[ 3 H]TCP Ligand Binding Assay. [ 3 H]TCP is a ligand that binds to the phencyclidine (PCP) binding site inside the NMDA receptor channel. It has been widely used to identify the presence of the NMDA receptor as well as to examine the status of activation of the NMDA receptor-coupled ion channel McNamara, 1988, 1989; Kloog et al., 1988; McDonald et al., 1989; Stirling et al., 1989; Yeh et al., 1989) . The binding of [ 3 H]TCP in the NMDA channel requires opening of the NMDA receptor-coupled ion channel, which is controlled by the agonist binding on the NMDA binding site and strychnine-insensitive glycine binding sites (Johnson and Ascher, 1987; Kleckner and Dingledine, 1988; McNamara, 1988, 1989; Kloog et al., 1988 Primary Rat Cortical Cell Cultures. Rat embryos of gestational days 15 to 17 were removed under ether anesthesia, and the cortexes were dissected and freed from the meninges. The tissues were then incubated with 0.25% trypsin in Ca 2ϩ /Mg 2ϩ -free modified Eagle's medium (MEM) at 37°C for 60 min. The enzyme solution was removed by aspiration, and tissues were washed with MEM containing 0.02% DNase I. Cells were mechanically dissociated by repetitive pipetting with a fire-polished glass pipette. After low-speed centrifugation, the resulting cell-containing pellet was re-suspended in MEM containing 5% fetal calf serum and 5% horse serum. The cells were plated in D-poly-lysine coated 6-well culture plates (9.62 cm 2 ) at a final cell density of 3-5 ϫ 10 5 cells/ml, and maintained for 12 to 15 days in a humidified CO 2 incubator. In the preliminary studies, some cultures were stained with immunocytochemical assay using antineuron-specific enolase (Chemicon International, Temecula, CA) and anti-glial fibrillary acidic protein (Chemicon) antibodies to determine the proportion of neuron and glial cell. Intracellular 45 Ca 2؉ Accumulation Assay. Primary cortical cell cultures at 12 to 15 days in vitro were incubated with 0.1 Ci/ml 45 Ca 2ϩ , 100 M NMDA, and 10 M glycine in the absence or presence of AMPH or other compounds for 2 min. The cells were washed with fresh MEM buffer three times and disrupted by 0.5 ml of 1% SDS. Radioactivities of cell solutions were counted by a liquid scintillating counter. The nonspecific 45 Ca 2ϩ accumulation was the 45 Ca 2ϩ accumulation in the cell culture incubated with 100 M NMDA, 10 M glycine, and 10 M MK-801, which was about 10 to 20% of total calcium accumulation in the presence of NMDA and glycine, and was subtracted from each collected value. The 2-min incubation time was chosen according to our preliminary study, which showed that the maximal inhibition produced by low concentrations of AMPH (from 0.1 M to 3 M) on the NMDA-and glycineelicited 45 Ca 2ϩ accumulation gradually decreased once the incubation time of AMPH and NMDA exceeded 5 min, and no significant inhibition could be observed when the incubation time exceeded 20 min. Similar phenomenon also found on the effect of NMDA receptor antagonists, like D-APV and MK-801. Their inhibitory efficacy gradually decreased, as incubation time exceeded 10 min. No inhibition was found when incubation time was exceeded 30 min. Thus, this phenomenon is likely due to the continuous accumulation of 45 Ca 2ϩ inside the cells through the unblocked NMDA receptor channel as time passed, which would finally saturated all the neuronal cells similar to that without the presence of antagonist. Therefore, a 2-min incubation was optimal to display the inhibitory effect of low concentrations of AMPH. Lactate Dehydrogenase (LDH) Assay in Primary Cortical Cell Cultures. Cultured cells with 12 to 15 days in vitro were exposed to 100 M NMDA and 10 M glycine in the presence or absence of additional compounds for 30 min. A 0.2-ml medium was sampled 24 h after NMDA and glycine was washed away with fresh MEM. LDH was measured using an LDH-detecting kit (Sigma). Nonspecific LDH values were the values of cultures incubated with 100 M NMDA, 10 M glycine, and 10 M MK-801 for 30 min and were subtracted from each collected value. Pictures of some cultured cells were taken 24 h after addition of drugs under a phase microscope (20 ϫ 20).
Statistics. The EC 50 or IC 50 values of compounds were determined using a nonlinear computerized curve fitting program (GraphPad Prism software, San Diego, CA), and one-and two-site analyses were compared with determine the best fit. The K d and B max of [ 3 H]TCP were determined using a nonlinear computerized curve fitting program (EBDA). Other data were analyzed with either Student's t test or with one-way ANOVA followed by a post hoc test, as appropriate. Results were considered significant when the calculated p value was Ͻ0.05. All data are reported as mean Ϯ S.E.M. McNamara, 1988, 1989; Yeh et al., 1990) . NMDA receptor agonist, like NMDA or glycine, will increase both the association rate and dissociation rate of [ 3 H]TCP. On the contrary, antagonist of NMDA receptor, like D-APV, will decrease both parameters. Consistent with this idea, the addition of D-APV concentration-dependently decreased both the association rate and dissociation rate in a parallel manner (Fig. 3, A and  B) . The association rate of [ 3 H]TCP calculated from 30-min incubation in the presence of 0 M, 1 M, 30 M, and 300 M D-APV was 9.2 Ϯ 0.6 fmol/mg/min (n ϭ 4), 7.4 Ϯ 0.4 fmol/mg/ min (n ϭ 4), 4.2 Ϯ 0.6 fmol/mg/min (n ϭ 4), and 1.7 Ϯ0.4 fmol/mg/min (n ϭ 4), respectively. All the association rates were significantly different to each other (p Ͻ 0.05, one-way ANOVA with Newman-Keuls test). Likewise, the dissociation rate of [ 3 H]TCP in the presence of D-APV was 6.3 Ϯ 0.4 fmol/mg/min (n ϭ 4), 4.4 Ϯ 0.3 fmol/mg/min (n ϭ 4), 2.3 Ϯ 0.3 fmol/mg/min (n ϭ 4), and 1.2 Ϯ 0.4 fmol/mg/min (n ϭ 4), respectively. The addition of d-AMPH could also decrease both the association rate and dissociation rate of [ 3 H]TCP but in a different manner (Fig. 3C, 3D) . d-AMPH concentrationdependently decreased the association of [
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3 H]TCP. The asso- 3 H]glycine binding with IC 50 of 47 Ϯ 9 nM (n ϭ 3) (data not shown). However, d-AMPH (from 0.1 to 100 M) did not significantly affect these two ligand bindings (Fig. 4) .
AMPH Inhibited the NMDA-and Glycine-Elicited Intracellular 45 Ca 2؉ Accumulation in Primary Rat Cortical Cell Cultures. To further verify the antagonism of AMPH analogs on the NMDA receptor, as revealed by the ligand binding study, we examined the effects of AMPH analogs on the NMDA-and glycine-elicited intracellular 45 Ca 2ϩ accumulation and cell death in the primary rat cortical cell cultures. In the preliminary immunocytochemical studies on this cell culture, we found that this primary cor- (Choi, 1990) . A 30-min incubation of NMDA induced apparent cell death as visualized by phase microscopy (data not shown). Addition of d-AMPH attenuated the NMDA-induced cell loss in a concentration-dependent manner, and d-AMPH alone did not produce apparent cell death. We used the LDH assay as a quantitative measurement for cell death. NMDA induced LDH release in a concentration-dependent manner with EC 50 of 35 Ϯ 15 M. Addition of 10 M glycine did not further increase the NMDA-induced LDH release. The effect of NMDA (100 M) could be abolished by NMDA receptor antagonists 10 M MK-801, 10 M TCP, 100 M dextromethorphan, or 500 M D-APV (data not shown). The inhibitory potency of MK-801, TCP, or dextromethorphan was 0.11Ϯ 0.04 M (n ϭ 3), 0.21 Ϯ 0.07 M (n ϭ 3), and 33 Ϯ 5 M (n ϭ 3), respectively (data not shown). AMPH analogs alone did not increase the LDH release, but concentrationdependently inhibited NMDA-and glcyine-induced increase in the LDH concentration (Fig. 6) . The IC 50 of d-AMPH and l-AMPH was 217Ϯ 32 and 192Ϯ 24 M, respectively. The IC 50 of MAMPH could not be calculated because the maximal inhibition for 1 mM MAMPH was less than 50%. It is noted that low concentrations (Ͻ10 M) of these three AMPH analogs did not have any significant effect on the NMDA-and glycine-induced LDH release.
Addition of Dopamine Receptor Antagonists, Chloropromazine, Haloperidol, and S(؊)Sulpride Did Not Reverse the Inhibitory Effect of AMPH on the NMDAand Glycine-Elicited 45 Ca ؉2 Accumulation and NMDAElicited LDH Release in the Primary Cortical Cell Cultures. To exclude the possibility that activation of the dopamine receptor may contribute to the inhibitory effect of AMPH on the NMDA receptor, we examined whether 30 M chloropromazine, a nonselective dopamine receptor antagonist; 10 M haloperidol, a D1/D2 receptor antagonist; and 10 M S(Ϫ)sulpride, a D2 receptor selective antagonist, could reverse the inhibitory effect of d-AMPH on the NMDA-and glycine-elicited 45 Ca ϩ2 accumulation and LDH release in the primary cortical cell cultures. All these dopamine receptor antagonists did not affect the inhibitory effect of AMPH on the NMDA receptor-mediated responses (Fig. 7) .
Discussion
The principle finding in this report is that AMPH could inhibit the NMDA receptor-mediated biochemical responses in vitro, including [ 3 H]TCP binding in membrane preparation, and 45 Ca 2ϩ accumulation and cell death in primary cortical neuronal cultures. The finding that dopamine antagonists could not reverse the inhibitory effects of AMPH excludes the involvement of dopamine and its receptor. Therefore, these inhibitory effects are specific for AMPH, and are due to direct action of AMPH on the NMDA receptor/channel complex.
The inhibition of the NMDA receptor-mediated responses by AMPH is marked by the presence of two distinct potencies: a minor inhibitory effect with high potency (the high-potency effect) and a major inhibitory effect with low potency (the low-potency effect The reason for this disparity is not clear. However, the potencies of MK-801, TCP, and dextromethorphan in inhibiting NMDA-and glycine-elicited LDH release were also at least 10-fold lower than their potencies to inhibit [ 3 H]TCP binding, suggesting that the weaker potency for AMPH to inhibit LDH release was likely due to the relative insensitivity of LDH assay to estimate the potency of the noncompetitive antagonists. In addition, the lack of inhibition on LDH release by low concentrations of AMPH may be related to its relatively low efficacy of inhibition, which could not be revealed by the LDH assay.
According Stirling et al., 1989; Franklin and Murray, 1992; Berman and Murray, 1996) , which have been shown to compete with [
3 H]TCP binding in membrane preparation. Thus, our result suggests that AMPH at high concentrations may inhibit NMDA receptor-mediated responses by blocking the NMDA channel in its opening status, like noncompetitive antagonists of the NMDA receptor. The binding site for AMPH in the channel might be close to or at the PCP site. On the hand, the high-potency inhibitory effect of AMPH is likely a result from decreasing the accessibility of (Bonhaus and McNamara, 1988) . However, AMPH did not affect the glutamate or glycine binding to the NMDA receptor, and AMPH could only partially decrease the accessibility of [ 3 H]TCP, suggesting that AMPH, at low concentration, may act as a partial antagonist with a unique inhibitory mechanism on the agonist-induced activation of NMDA receptor-coupled ion channel.
The rank order of the potency for AMPH analogs in producing each of the two inhibitory effects on the NMDA receptor-mediated responses is quite different to each other. Although there is no significant rank order of the AMPH potency for the high-potency inhibitory effect, the rank order for the low-potency inhibitory effect is d-AMPHϷ l-AMPHϾ Ͼ MAMPH. This finding suggests that the interacting sites for these two inhibitory effects of AMPH are independent to each other. Thus, we tentatively propose that AMPH could directly interacting with two different sites on the receptor/ channel complex; namely a high-affinity site in partially inhibiting the activation of NMDA receptor channel and a low-affinity site in blocking the channel. However, our result could not exclude the possibility that the multiple potencies for AMPH to inhibit NMDA receptor-mediated responses are due to two different populations of the NMDA receptor with different sensitivity to inhibition by amphetamine, because existence of heterogenicity of the NMDA receptor population in the brain has been reported previously (Audinat et al., 1994; Farrant et al., 1994) . But, the difference in the underlying mechanism between the high-and low-potency effect of AMPH suggests that this possibility is less likely than the suggestion for two distinct interacting sites for AMPH on the NMDA receptor. (Paul and Hulihan-Giblin, 1982; Hauger et al., 1984) . In general, the binding affinities of [
3 H]AMPH were all within a few-hundred nanomolar range. These affinities were close to that of the high-affinity site for AMPH on the NMDA receptor suggested by the present study. However, the density of [ 3 H]AMPH binding is highest in the hypothalamus and brainstem and is quite low in the cortex and hippocampus. This regional distribution is in contrast to the distribution of the NMDA receptor in the brain, in which the cortex and hippocampus are enriched with the NMDA receptor, whereas the hypothalamus has a very low density of this receptor. Such lack of correlation in the regional distribution suggests that the majority of the specific [ 3 H]AMPH binding sites are not identical with the AMPH interacting sites on the NMDA receptors.
Whether AMPH can inhibit the NMDA receptor-mediated neurotransmission in vivo will depend on the ambient concentration of AMPH in the brain circuits using the NMDA receptor. Theoretically, the ambient concentration of AMPH in brain circuit is primarily decided by the dosage of AMPH injected, and by the repetition of injection. So far, there is very limited information regarding the concentration of AMPH in vivo. One particular study had estimated that the extracellular concentration of AMPH in striatum could reach about 2.8, 5.6, and 11.9 M after single injection of 1, 2.5, and 5 mg/kg AMPH, respectively. The concentration of AMPH could further approach to 30 M after repeated injection of 15 mg/kg AMPH (Clausing et al., 1995) . If this measurement of AMPH concentration is applicable, and our estimation of potencies of AMPH on the NMDA receptor is correct, single low dose AMPH (1-2.5 mg/kg) injection should provide sufficient ambient concentration of AMPH, at least in striatum, to saturate the high-affinity site of AMPH on the NMDA receptor. On the other hand, repeated injection of high dose AMPH (up to 15 mg/kg) should able to provide sufficient concentration of AMPH to interact with the lower-affinity site on the NMDA receptor to a significant extent. Nevertheless, one should be aware that the inhibitory potencies of AMPH revealed by the present biochemical assays might be not the true potencies for AMPH once applied into neuron in vivo. For more accurate estimation, electrophysiological assay using whole cell or patch clamp will be necessary.
In general, a single injection of 1 to 2.5 mg/kg AMPH could induce behavioral change, and repeated injections of these dosages will lead to behavioral sensitization. Single or repeated injections of 5 to 10 mg/kg will be neurotoxic, especially in the dopaminergic system. This raises the possibility that the antagonism property on NMDA receptor might contribute to the AMPH-induced neuropathologies if sufficient concentration of AMPH could be in the brain circuit using the NMDA receptor. However, this possibility seems to be incompatible with the general idea that activation of the NMDA receptor is required for AMPH-induced responses (Karler et al., 1989; Lowy, 1990; Hemrick-Luecke et al., 1992; Bristow et al., 1994; Wang et al., 1994; Konradi et al., 1996) . Alternatively, our result may suggest that AMPH, by acting as a NMDA receptor antagonist, is neuroprotective against other neuropathologies related to over-activation of the NMDA receptor, like hypoxia-ischemia insult in brain circuits enriched with this receptor. For instance, one report has shown that repeated treatment of AMPH (2 mg/kg every 3 days) in rats Amphetamine Inhibits NMDA Receptor-Mediated Responses after neocortical infarction induced by ischemia accelerated neocortical neural sprouting, synaptogenesis, and behavioral recovery (Stroemer et al., 1998) . The underlying mechanism for this specific effect of AMPH was not yet identified. Thus, it is worthy to determine whether the direct inhibition of AMPH on the NMDA receptor may contribute to the enhancement of neural recovery by attenuating the progression of neurodegeneration processes mediated by the NMDA receptor after the insult.
In summary, our study disclosed a novel pathway for AMPH to influence the neuronal functions in the brain by directly inhibiting the NMDA receptor, and two distinct interacting sites on this receptor/channel complex for AMPH are strongly suggested. Further investigations toward the verification of this inhibition in vivo and identification of the functional significance of this specific antagonism effect of AMPH are necessary.
